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Unregulated cellular uptake of apolipoprotein B-containing lipoproteins in the arterial intima
leads to the formation of foam cells in atherosclerosis. Lysosomal acid lipase (LAL) plays
a crucial role in both lipoprotein lipid catabolism and excess lipid accumulation as it is
the primary enzyme that hydrolyzes cholesteryl esters derived from both low density
lipoprotein (LDL) and modified forms of LDL. Evidence suggests that as atherosclerosis
progresses, accumulation of excess free cholesterol in lysosomes leads to impairment of
LAL activity, resulting in accumulation of cholesteryl esters in the lysosome as well as the
cytosol in foam cells. Impaired metabolism and release of cholesterol from lysosomes can
lead to downstream defects in ATP-binding cassette transporter A1 regulation, needed to
offload excess cholesterol from plaque foam cells. This review focuses on the role LAL
plays in normal cholesterol metabolism and how the associated changes in its enzymatic
activity may ultimately contribute to atherosclerosis progression.
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INTRODUCTION
Atherosclerosis is characterized biochemically by the accumu-
lation of excess cholesterol in the artery wall. This process is
initiated by migration of low density lipoproteins (LDL) and
other apolipoprotein B (apoB)-containing lipoproteins across an
injured artery endothelium, where they are retained through
a charge-charge interaction with matrix proteoglycans in the
subendothelial space (Tabas et al., 2007). Within this space the
trapped lipoproteins are subject to modification including oxi-
dation and aggregation, converting them to ligands for scav-
enger receptors on intimal macrophages and smooth muscle cells
(SMCs). Excessive scavenger receptor-mediated uptake of mod-
ified lipoproteins leads to accumulation of cytosolic cholesteryl
ester (CE) droplets in these cells, giving them a “foamy” appear-
ance microscopically, hence their name foam cells. There is also
evidence that at later stages of atherosclerosis, both free choles-
terol (FC) and CE droplets accumulate within the lysosome itself
(Jerome, 2006). Lysosomal acid lipase (LAL) plays the central role
in hydrolyzing lipoprotein CE to generate FC, which after leaving
the lysosome can be re-esterified in the endoplasmic reticulum to
form cytosolic lipid droplets. If excess FC is retained in the lyso-
some it can inhibit lysosomal activity including that of LAL. The
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physiologic role of LAL may therefore lead to eventual inhibition
of LAL activity in the presence of excess atherogenic lipoprotein
uptake, contributing further to the progression of atherosclerosis.
LYSOSOMAL ACID LIPASE
GENE EXPRESSION AND MUTATION
LAL is the enzyme with primary responsibility for hydrolysis
of CE and triglycerides in lipoproteins taken up by receptor-
mediated endocytosis. LAL has been called by several names,
including lipase A, acid cholesteryl ester hydrolase, acid choles-
terol esterase, and acid cholesteryl esterase. LAL is a 46 kDa
glycoprotein whose gene LIPA is found on chromosome 10q23.2-
23.3 (Anderson et al., 1993). Human LAL cDNA encodes a
372-amino acid mature protein and a 27-amino acid signaling
sequence (Ameis et al., 1994). After undergoing co-translational
glycosylation in the endoplasmic reticulum and attachment of
mannose-6-phosphate residues in the Golgi apparatus, LAL is tar-
geted to pre-lysosomal compartments (Sando and Henke, 1982;
Sheriff et al., 1995). Mutations of LIPA result in complete defi-
ciency of LAL in patients with Wolman disease, which is fatal in
the first year of life without LAL replacement, or near-total and
non-fatal deficiency known as Cholesteryl Ester Storage Disease
(CESD). The most common mutation seen in CESD patients
is a splice junction mutation at exon 8 of LIPA, which leads
to ∼3–5% of normally spliced LAL protein and LAL activity
(Scott et al., 2013; Stitziel et al., 2013). In addition to having
fatty liver and spleen enlargement, individuals with CESD have
elevated LDL-Cholesterol, low HDL-Cholesterol, and develop
premature atherosclerosis, indicating the critical role LAL plays in
cellular cholesterol and lipoprotein metabolism (Bernstein et al.,
2013; Grabowski et al., 2014).
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TRANSCRIPTIONAL REGULATION
Several reports have demonstrated an increase in LAL mRNA and
protein in the artery wall during the progression of atheroscle-
rosis. Ries et al. (1998) reported that LAL mRNA is increased
as human blood monocytes differentiate to macrophages, and
that increases in LAL mRNA resulted in higher amounts
of LAL enzyme within differentiated macrophages. Therefore,
macrophages expressing increased levels of LALmay contribute to
the increased LAL activity in the atherosclerotic relative to normal
artery wall.
LAL has been shown to be regulated by transcription factors
involved in the autophagy pathway. The transcription factor
forkhead homeobox type protein O1 (FOXO1) is upregulated
in response to nutrient restriction (Sandri, 2012), and has
been shown to upregulate LIPA in adipocytes as part of the
autophagy response (Lettieri Barbato et al., 2013). It has also been
reported that the basic helix-loop-helix (bHLH) transcription
factor EB (TFEB), described as a master regulator of autophagy
and lysosomal biogenesis, targets the LIPA gene (Sardiello et al.,
2009). When cellular nutrient conditions are plentiful TFEB is
phosphorylated by mammalian target of Rapamycin complex 1
(mTORC1) and is located in the cytosol on the lysosomal mem-
brane (Settembre et al., 2012). The reader is directed elsewhere
for further information regarding upstream signaling mecha-
nisms of autophagy through mTORC1 (He and Klionsky, 2009;
Efeyan et al., 2012; Shanware et al., 2013; Sergin and Razani,
2014). Under conditions of starvation and lysosomal stress TFEB
is dephosphorylated and translocates to the nucleus for upreg-
ulation of genes involved in the lysosomal-autophagic pathway
(Settembre et al., 2013). Recently it has been reported that over-
expression of TFEB led to a 2.5-fold increase in LIPA mRNA in
mouse peritoneal macrophages (Emanuel et al., 2014). Whether
such an upregulation occurs in response to physiologic excur-
sions of TFEB expression is not yet known. Translocation of TFEB
to the nucleus and a modest (0.2-fold) upregulation of LIPA
also occurred after a 12 h incubation of peritoneal macrophages
with oxidized LDL (oxLDL); the TFEB nuclear localization was
reduced at 24 h of oxLDL incubation, however, indicating this
response of LIPA is likely mild and transient (Emanuel et al.,
2014). Heltianu et al. (2011) reported no change in LIPA expres-
sion in SMCs and a 20% reduction in LIPA expression in endothe-
lial cells incubated with oxLDL for 24 h. Further studies are
required to confirm the importance and cell specificity of TFEB-
dependent upregulation of LIPA in response to modified forms of
LDL and cellular stress induced by excess cell cholesterol.
It has also been demonstrated by Heltianu et al. (2011) that in
some cell types LIPA expression increases with liver-X-receptor
(LXR) and peroxisome proliferator-activated receptor (PPAR)
agonists. LIPA is not known to contain an LXR or PPAR response
element in its promoter region. Bowden et al. (2011) demon-
strated in CESD fibroblasts that the LXR agonist TO901317
failed to correct LDL-CE hydrolysis and cholesterol efflux to
apolipoprotein A1 (apoA1), indicating the residual expression of
LAL in CESD cells was not increased by the LXR agonist. LIPA
response to LXR and PPARγ agonists may be cell type specific
and involve stimulation of the autophagy pathway. LXR is not a
known target of TFEB, whereas peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC-1α), which interacts
with PPARγ, is a transcriptional target of TFEB (Sardiello et al.,
2009).
Our understanding of the transcriptional regulation of LIPA
in the artery wall during the progression of atherosclerosis is
far from complete. Initially it was hypothesized by De Duve
(1974) that a deficiency in LAL was the cause of intracellu-
lar accumulations of lipids in atherosclerosis. Supporting this
hypothesis was the observation of lipid-engorged lysosomes in
post-mortem liver tissue samples from Wolman disease patients
having complete absence of LAL (Patrick and Lake, 1969; Lake
and Patrick, 1970) and premature atherosclerosis seen in the near-
total LAL deficiency CESD (Sloan and Fredrickson, 1972). Several
groups subsequently reported that LAL activity was increased in
atherosclerotic tissue (Brecher et al., 1977; Takano, 1978; Subbiah,
1979). Haley et al. (1980) indicated a 2-fold increase in LAL
activity in lipid-laden lysosomes isolated by density centrifuga-
tion from atherosclerotic tissue homogenates. Davis et al. (1985)
reported that increased LAL activity in human aortic lesions at
various stages of disease correlated with increased macrophage
infiltration. These studies do not support the LAL deficiency
hypothesis of atherosclerosis. It is not yet clear whether increased
LAL in atherosclerotic tissue is a result of upregulation of LAL
within cells or a higher number of LAL-expressing cells present in
the lesion, but potentially both.
REGULATORY ROLE OF LYSOSOMALLY-DERIVED CHOLESTEROL
Cholesterol is a component of all cell membranes, and is the
precursor for oxysterol, steroid hormone, bile acid, and vita-
min D synthesis. FC released by lysosomes from lipoprotein and
membrane turnover is an important substrate pool for these
metabolites. In addition the lysosomally-derived cholesterol pool
has multiple regulatory roles through inhibition of sterol regula-
tory element binding protein (SREBP) cleavage activating protein
(SCAP) in the endoplasmic reticulum, and downregulation of
SREBP-dependent new cholesterol synthesis and LDL receptor
expression by the cell (Brown and Goldstein, 1997). In this
way cholesterol released from lysosomes is a critical regulator of
overall cell cholesterol homeostasis. When flux of FC from lyso-
somes is high, oxysterol levels including 27-hydroxycholesterol
are increased and bind to the nuclear receptor liver X receptor
(LXR), which activates transcription of several genes involved in
the removal of cholesterol from cells and other steps in reverse
cholesterol transport (Venkateswaran et al., 2000). One of these
genes encodes the ATP-binding cassette transporter A1 (ABCA1),
a plasma membrane protein that promotes cholesterol efflux to
apoA1, the rate-limiting step in the formation of high density
lipoproteins (HDL) (Oram and Heinecke, 2005). The impor-
tance of lysosomally-derived cholesterol in, and the inability
of increased de novo synthesis of cholesterol (Goldstein et al.,
1975; Liscum and Faust, 1987) to correct, ABCA1 expression
has been demonstrated in the lysosomal cholesterol storage dis-
orders Niemann Pick Disease type C (NPC) and CESD (Choi
et al., 2003; Bowden et al., 2011). In both cases the reduced flux
of FC out of lysosomes leads to reduced 27-hydroxycholesterol
production and reduced ABCA1 expression, the likely cause of
low plasma HDL-C in both these disorders (Garver et al., 2010;
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Bernstein et al., 2013). Delivery of exogenous oxysterols to NPC
fibroblasts (Boadu et al., 2006) and recombinant human LAL to
CESD fibroblasts (Bowden et al., 2011) were both able to correct
ABCA1 expression and cholesterol efflux to apoA1. This indicates
that the rate of release of FC from the lysosome after both LAL-
dependent CE hydrolysis and the action of Niemann Pick type C1
(NPC1) protein in the lysosomal membrane is a critical determi-
nant of cholesterol-dependent gene regulation. As hydrolysis of
CE derived from both LDL and modified LDL in the lysosome
is also likely to be a key regulator of ABCA1 expression in cells
in atherosclerotic lesions, a defect in LAL activity could result in
impaired ABCA1-dependent cholesterol efflux from macrophage
and SMC foam cells.
LIPOPROTEIN UPTAKE AND LIPID ACCUMULATION
Uptake of LDL through cell surface LDL-receptors is tightly reg-
ulated and therefore insufficient to explain intimal foam cell
formation (Goldstein and Brown, 1977, 2009). Within the artery
wall LDL and other apoB-containing particles become oxidized,
aggregated, or enzymatically-modified (Aviram, 1993; Bhakdi
et al., 1995; Hoff and Hoppe, 1995; Chisolm and Steinberg, 2000;
Torzewski and Lackner, 2006) (Figure 1). These altered forms
of LDL are no longer recognized by the LDL receptor but are
recognized and taken up by scavenger receptors expressed on
macrophages and SMCs, a cellular process that is not feedback
regulated and can lead to massive accumulation of cholesterol
in these cells (Brown et al., 1979; Brown and Goldstein, 1983;
Moore and Freeman, 2006). Scavenger receptors as well as the
LDL receptor utilize the endocytic pathway for delivery of cargo
to lysosomes. Lipoprotein cholesterol is primarily in the form
of CE, which is hydrolyzed within lysosomes by LAL, the only
lysosomal lipase known to perform this function (Brown et al.,
1975; Goldstein and Brown, 1977; Aviram, 1993; Dhaliwal and
Steinbrecher, 2000; Yancey and Jerome, 2001; Griffin et al., 2005).
LAL in the lysosome is most catalytically active at pH 3.5–
4.5 (Takano et al., 1974; Haley et al., 1980). The FC released
from lipoprotein CE is transported out of the lysosome by the
concerted actions of the Niemann-Pick Type C2 (NPC2) and
NPC1 lysosomal proteins, with one fate of the FC then being
re-esterification in the endoplasmic reticulum by acyl-coenzyme
FIGURE 1 | Cholesterol metabolism in atherosclerotic lesion foam cells.
LDL and other apoB-containing lipoproteins pass through the damaged
endothelium and undergo aggregation, oxidation, and enzymatic modification
within the intima of the arterial wall. SMCs from the media migrate to the
intima and contribute to diffuse intimal thickening (DIT). Monocytes enter
through the damaged endothelium and differentiate into macrophages. SMCs
and macrophages take up aggLDL, oxLDL, and enzymatically-modified LDL
(E-LDL) through scavenger receptors in an unregulated manner, and deliver
their cargo to the lysosome through the endocytic pathway. Within the
lysosome, lipoprotein cholesteryl esters (CE) are hydrolyzed by LAL to
generate free cholesterol (FC). The pH of the lysosome is acidified by the
proton pumping action of v-ATPases. FC leaves the lysosome through the
concerted action of NPC2 and NPC1 proteins and is transported within the
cell including to the endoplasmic reticulum (ER) where it is re-esterified by
ACAT and accumulates as lipid droplets within the cytosol. CE in lipid
droplets can be hydrolyzed by nCEH and used for cellular functions or
removed from the cell along with phospholipids by the actions of ABCA1 to
create new HDL particles. CE in lipid droplets can also be transported back to
the lysosome through the lipophagy pathway for hydrolysis by LAL and
cellular removal of FC via ABCA1. Early atherosclerotic lesion foam cell lipid
droplets are primarily cytosolic whereas later stage lesion foam cells contain
a mixture of ACAT-derived lipid droplets and lysosomal lipid droplets.
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A:cholesterol acyltransferase (ACAT) (Kwon et al., 2009). Re-
esterification is a protective mechanism to prevent the toxicity
of excess FC in membranes (Tabas, 2002), particularly in the
endoplasmic reticulum, with the reformed CE then stored in the
cytoplasm as benign lipid droplets (Brown and Goldstein, 1983).
CE in foam cell cytosolic lipid droplets can be transported back
to lysosomes through the autophagic process termed “lipophagy”
(Singh et al., 2009); cholesterol derived from this process appears
to form a large part of the substrate pool of ABCA1 for efflux from
cells (Ouimet et al., 2011).
During early stages of atherosclerosis foam cells appear as vis-
ible fatty streaks in the intima of the artery wall (Haust, 1971). In
addition to the presence of macrophage derived foam cells, SMCs
present in the intima beginning in the pre-atherosclerotic diffuse
intimal thickening stage also take up modified forms of LDL via
scavenger receptors to become smooth muscle derived foam cells
(Li et al., 1995; Doran et al., 2008). It has been previously thought
macrophages were the major contributors to foam cells in the
intima, however recent studies from our lab suggest SMCs are
the source of more than 50% of the total foam cell population
in human coronary artery atherosclerotic lesions (Allahverdian
et al., 2014).
OVERACCUMULATION OF CHOLESTEROL IN LYSOSOMES
Retention of LDL and other apoB-containing lipoproteins in the
arterial intima by matrix proteoglycans, as a result of charge-
charge interactions (Williams and Tabas, 1995, 2005), means
these lipoproteins are susceptible to modification to more athero-
genic forms. This modification, either by enzymes, oxidants, or
through aggregation converts these lipoproteins to ligands for
scavenger receptors and allows for the formation of cholesterol-
overloaded foam cells (Hoff and Hoppe, 1995; Torzewski and
Lackner, 2006). Within the intima LDL has been demonstrated
to undergo both extracellular and intracellular modifications
(Aviram, 1993; Bhakdi et al., 1995; Hoff and Hoppe, 1995;
Torzewski et al., 1998; Chisolm and Steinberg, 2000; Steinberg
and Witztum, 2002; Stocker and Keaney, 2004; Wen and Leake,
2007). LAL and lysosomal enzymes have also been implicated in
the modification of LDL, and, conversely, modified forms of LDL
have been shown to affect lysosomal function and lead to changes
in LAL activity.
EXTRACELLULAR MODIFICATION OF LDL BY LAL
LAL is present within the extracellular space of atherosclerotic
intima (Hakala et al., 2003), and there are indications that LAL
may actively participate in the modification of retained LDL.
Secretion of lysosomal enzymes by macrophages is known to
occur without stimuli, and increase under inflammatory condi-
tions (Schnyder and Baggiolini, 1978). Catalytic activity of LAL
would require conditions of at least localized reduced pH in
the extracellular space. Naghavi et al. (2002) reported that pH
heterogeneity exists within atherosclerotic lesions with increased
acidity in lipid-rich, macrophage-containing areas compared to
calcified areas of human and rabbit atherosclerotic plaque.Micro-
environments with much lower pH supportive of LAL activity
may exist within lesions, as macrophages can acidify their peri-
cellular space through the action of proton pumps (Tapper and
Sundler, 1992) and by secreting lactic acid (Newsholme et al.,
1987). Buton et al. (1999) reported that CE present in matrix-
retained aggregated LDL (aggLDL) may be hydrolyzed by LAL
during extensive cell-surface contact with cultured macrophages.
Fluorescence microscopy was utilized to indicate that the matrix-
retained aggLDL was present on the cell surface during CE
hydrolysis; definitive proof that the observed CE hydrolysis is
extracellular is still needed. Thus, LAL might be present in a cat-
alytically active form in the pericellular space of macrophages
within lesions, which could contribute to extracellular CE hydrol-
ysis and atherogenic modification of apoB containing particles.
In support of CE hydrolysis of LDL increasing the atherogenicity
of LDL, human macrophages have been shown to take up LDL
modified by hydrolysis with neutral cholesteryl ester hydrolase
(nCEH) at a rate exceeding that of oxLDL or acLDL (Bhakdi et al.,
1995). Further evidence is required to know whether extracellu-
lar hydrolysis of LDL CE by LAL increases uptake of the modified
LDL by scavenger receptors.
OXIDATIVE MODIFICATION OF LDL
Oxidation of LDL is proposed to contribute to foam cell for-
mation by virtue of oxLDL being a ligand for scavenger recep-
tors. The presence of oxLDL within atherosclerotic lesions has
been demonstrated by immunostaining using antibodies gen-
erated against oxLDL epitopes (Mehrabi et al., 2000). Within
the artery wall, oxidation of LDL may occur by a number of
concurrent mechanisms involving enzymes (e.g., myeloperox-
idase, NADPH oxidase, lipoxygenase, and xanthine oxidase),
peroxynitrite-generators, superoxide, low levels of metal ions,
and thiols (Gaut and Heinecke, 2001; Parthasarathy et al., 2010;
Yoshida and Kisugi, 2010), and is thought to occur mainly within
the interstitial fluid of atherosclerotic lesions.
The presence of oxidized sterols within human atheroscle-
rotic tissue and lesion LDL has been reported. Steinbrecher and
Lougheed (1992) found 7-ketocholesterol, 7-hydroxycholesterol,
and 5,6-epoxycholesterol in LDL isolated from atherosclerotic
but not healthy aortas. Significant accumulations of oxysterols
are present in atherosclerotic lesions (Brown and Jessup, 1999).
Quantitative comparison of in vitro studies conducted using
oxLDL is difficult due to the variety of methods by which LDL is
oxidized and the degree of oxidation induced (Yancey and Jerome,
2001; Orso et al., 2011). Oxidative modification of apoB by oxi-
dized lipids reduces recognition of LDL by the LDL receptor
and increases its affinity for scavenger receptors, making oxLDL
a potent promoter of foam cell formation in vitro (Jessup and
Kritharides, 2000). In vitro studies show a significant fraction of
the sterols present in oxLDL are retained within the lysosome and
that oxidized CE are resistant to hydrolysis by LAL (Yancey and
Jerome, 1998; Brown et al., 2000). Of note, LDL isolated from
human atherosclerotic plaques was found to be largely aggregated
and only mildly oxidized (Steinbrecher and Lougheed, 1992; Niu
et al., 1999).
AGGREGATION OF LDL
Isolated aortic LDL fractions from human lesions are
potent inducers of macrophage CE accumulation rel-
ative to normal aortic LDL fractions and plasma LDL
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(Goldstein et al., 1981; Hoff andMorton, 1985). Steinbrecher and
Lougheed (1992) demonstrated that this affect was due primarily
to aggLDL isolated from human atheromas. The presence of
aggLDL in the extracellular space of human atherosclerotic tissue
was also reported using electron microscopy (Guyton and Klemp,
1993). In vivo, aggregation of LDL may be a result of a variety
of stimuli including oxidation, extracellular matrix interactions,
phospholipase A2 and C, sphingomyelinase, and glycosylation
(Falcone and Salisbury, 1988; Suits et al., 1989; Hoff et al., 1990;
Xu and Tabas, 1991; Tertov et al., 1992; Maor and Aviram, 1999;
Xu and Lin, 2001; Kruth, 2002). As oxidation is known to cause
aggregation of LDL it may be difficult to separate the relative
contributions of oxLDL and aggLDL to foam cell (Figure 2)
formation in the atherosclerotic intima.
EFFECTS OF EXCESS MODIFIED LDL UPTAKE ON
LYSOSOMAL HYDROLYTIC FUNCTION
Previous studies have reported variable effects of different
forms of modified LDL on accumulation of cholesterol either
in the cytosol alone or also in lysosomes, with oxLDL and
aggLDL causing accumulation of cholesterol in lysosomes, while
enzymatically-modified and acetylated LDL cause mainly cytoso-
lic accumulations (Yancey and Jerome, 2001; Griffin et al., 2005;
Orso et al., 2011). Treatment of THP-1 macrophages in culture
withmildly oxLDL or aggLDL shows similar trends in loss of lyso-
somal hydrolysis (Yancey and Jerome, 2001; Griffin et al., 2005).
Initially CE hydrolysis is not inhibited but lysosomal sequestra-
tion of FC occurs. After prolonged exposure to mildly oxLDL
or aggLDL (48 h or more) increasing inhibition of CE hydrol-
ysis occurs and lysosomal accumulation switches to mainly CE
(Yancey and Jerome, 2001; Griffin et al., 2005).
Some variability between species has been observed (Griffin
et al., 2005). Yancey and Jerome (1998) reported that THP-
1 human macrophages and pigeon macrophages store FC and
CE derived from mildly oxLDL within lysosomal compartments,
whereas mouse macrophages stored most of the cholesterol
in cytosolic lipid droplets. Interestingly, acLDL was efficiently
FIGURE 2 | Human monocyte derived macrophage foam cells. Foam
cells were generated by incubation of macrophages with 100μg/mL
aggregated LDL for 48 h. Cells were then fixed and intracellular lipids
stained using Oil Red O (image provided by Dubland, J. A.).
hydrolyzed in macrophages regardless of the species and led
to cytosolic lipid droplet accumulation (Yancey and Jerome,
1998). Maor and Aviram (1994) reported that the addition of
oxysterols isolated from oxLDL to medium when loading J-774
mouse macrophages with acLDL led to significant lysosomal FC
accumulations.
Cox et al. (2007) have reported a general loss of lysosomal
function including reduction in LAL-dependent CE hydrolysis
over time following incubation of THP-1 human macrophages
with mildly oxLDL or aggLDL. The similar effects using unox-
idized aggLDL and oxLDL suggest this inhibition of lysosomal
function is not specific to the effects of oxidized lipids. Increasing
levels of lysosomal membrane FC during lipid loading were
shown to inhibit lysosomal acidification (Cox et al., 2007). It was
demonstrated using fluorescence quenching studies that excess
FC in the lysosomal membrane leads to loss of acidity as a result
of inhibition of vacuolar H+-ATPase (v-ATPase) proton pump-
ing activity in the lysosomal membrane, without a change in the
amount of v-ATPase protein. The resultant increase in pH within
the lysosome corresponded with a time-dependent inhibition of
CE hydrolysis and accumulation of apoB, indicating a general
decline in lysosomal hydrolytic activity. After 7 days of incubation
with mildly oxLDL or aggLDL, the majority of lysosomal vesicles
within THP-1 macrophages had pH>4.8. Vacuolar ATPase activ-
ity could be partially recovered if isolated lysosomes were treated
with cyclodextrins in order to remove membrane cholesterol. As
LAL is only active at acidic pH, with maximal activity ∼pH 4
and very little activity above pH 4.5 (Burton et al., 1980; Haley
et al., 1980), this loss of v-ATPase activity in response to choles-
terol loading of the lysosomal membrane may be the main cause
of loss of hydrolytic activity of LAL, and hence lead to lysosomal
lipid droplet accumulations.
In contrast to oxLDL and aggLDL, incubation of THP-1
macrophages with acLDL, an experimental rather than physio-
logic form of modified LDL, did not result in an increase in
lysosomal membrane FC or an increase in lysosomal pH (Cox
et al., 2007). The reasons for the differential effects of acLDL and
oxLDL or aggLDL on sequestration of FC in lysosomal mem-
branes following hydrolysis by LAL are unknown. In order to
investigate if the observed neutralization of lysosomal pH and
inactivation of LAL following oxLDL uptake could be reversed
by acLDL, THP-1 macrophages were incubated for 3 days in the
presence of oxLDL to accumulate lysosomal CE and then chase
incubated with acLDL for an additional 3 days (Jerome et al.,
2008). Hydrolysis of CE in the chase acLDL incubation was inhib-
ited and the loss of acidic pH from the initial loading with oxLDL
was maintained, indicating lysosomal dysfunction was not readily
reversible. Similar results were found in humanmonocyte derived
macrophages. This data indicates that inhibition of LAL activity
is the result of a long-lived alteration in lysosomal function under
excess lipid loading.
Emanuel et al. (2014) also found a loss of lysosomal acid-
ity occurred in mouse peritoneal macrophages at 72 h of oxLDL
treatment and in isolated macrophages from atherosclerotic aor-
tic tissue of ApoE−/− mice. This group also reported that over-
expression of TFEB in mouse peritoneal macrophages was able to
preserve lysosomal acidity, by mechanisms that are not yet clear.
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An interesting study by Ullery-Ricewick et al. (2009) demon-
strated that in THP-1 human macrophages lysosomal CE accu-
mulations from aggLDL could be reduced by 50% by chase
incubation with triglyceride (TG)-rich lipid dispersions or VLDL.
It was shown that TG treatment reestablished acidic pH by restor-
ing proton pumping by v-ATPases in the lysosomal membrane
(Ullery-Ricewick et al., 2009). TGs also increased LAL activity,
with no change in LAL expression. The exact mechanism by
which TG-containing particles restore lysosomal function in foam
cells remains to be determined; however, it was demonstrated
to not be a result of competitive uptake of TG-rich vs. CE-rich
particles (Ullery-Ricewick et al., 2009). This is further evidence
that inhibition of v-ATPase proton pumping in the lysosomal
membrane leads to loss of LAL activity and lysosomal CE accu-
mulations, but may be reversible under some conditions. Further
investigation is needed to evaluate the role of TGs in lysosomes of
arterial wall foam cells, including the signaling role of TG-derived
fatty acids on the LXR and PPAR metabolic pathways.
An alternative or additional reason for the increase in lysoso-
mal pH is that excess membrane FC and oxidized FC can cause
lysosomal leakiness, leading to a loss of the proton gradient. Li
et al. (1998) reported that incubation of J-744 macrophages with
oxLDL resulted in leakage of lysosomal enzymes into the cytosol.
Yuan et al. (2000) found that a mixture of cholesterol oxida-
tion products found in oxLDL were also able to induce damage
to lysosomes and leakage of lysosomal contents into the cytosol,
and eventual macrophage cell death. Although leakiness was not
implicated in the studies by Cox et al. (2007) using mildly oxLDL
or aggLDL, as apoptosis was not observed, it may be a long term
contributing factor in vivo. The presence of free cholesterol crys-
tals has been reported in J774 macrophage foam cells (Tangirala
et al. (1994), and treatment of mouse peritoneal macrophages
with free cholesterol was shown to induce lysosomal membrane
leakiness (Emanuel et al. (2014). An increase in lysosomal pH has
also been shown to increase extracellular excretion of lysosomal
enzymes (Tapper and Sundler, 1990), which may contribute to
the extracellular LAL observed in atherosclerotic lesions (Hakala
et al., 2003). Overall it appears that increases in lysosomal FC
induce both defects in lysosome acidification and leakiness of the
lysosomal membrane.
Oxidation of apoB-100 has been reported to increase its
resistance to degradation by cathepsin D in mouse peritoneal
macrophages and its accumulation in lysosomal compartments
(Lougheed et al., 1991; Jessup et al., 1992; Roma et al., 1992;
Hoppe et al., 1994; Mander et al., 1994). Decreased apoB-100
protein degradation may also limit LAL mediated hydrolysis of
the CE lipid core of oxLDL. Oxidized phospholipids in oxLDL
can inhibit cathepsin D, which may explain the reduced ability to
degrade apoB (O’neil et al., 2003). Oxidized phosphatidylcholine-
apoB complexes have been found in human atherosclerotic
lesions and also in lysosomes of cultured mouse macrophages
incubated with oxLDL (Itabe et al., 2000). Brown et al. (2000)
found that oxidized CE from heavily oxidized LDL loading are
resistant to hydrolysis by LAL and accumulate in lysosomal com-
partments. Therefore, oxidative modifications to apoB containing
particles may lead to impaired lysosomal clearance for reasons
additional to those induced by non-oxidized aggLDL.
LYSOSOMAL CHOLESTEROL ACCUMULATION IN
ATHEROSCLEROSIS
In the absence of genetic deficiency in LAL, in vivo studies
including electron microscopy have indicated that, in addition
to storage of CE droplets in the cytoplasm, there are sub-
stantial accumulations of FC and CE within the lysosomes of
foam cells (Jerome and Yancey, 2003). This phenomenon has
been previously reported for both human (Coltoff-Schiller et al.,
1976) and animal (Peters et al., 1972; Shio et al., 1974, 1979;
Goldfischer et al., 1975; Fowler et al., 1980; Jerome and Lewis,
1985) atherosclerosis. It has been indicated that as atherosclerosis
progresses there is initially an increasing amount of FC retained
in lysosomes, and at later disease stages also retention of lyososo-
mal CE (Jerome, 2006). A possible conclusion that can be drawn
from this is that there is a general loss of lysosomal function due
to cholesterol overload following unregulated cellular uptake of
modified forms of LDL within artery wall cells. As LAL hydrolyzes
lipoprotein CE, the loss of LAL function due to excess FC within
the lysosome contributes to the formation of foam cells and the
altered distribution of lipid stores within these cells. Therefore,
atherosclerosis has been proposed as a type of lysosomal stor-
age disorder (Miller and Kothari, 1969; Peters et al., 1972; Peters
and De Duve, 1974; Shio et al., 1974; Coltoff-Schiller et al., 1976;
Jerome and Lewis, 1985).
As indicated above, the reason for the loss of lysosomal
hydrolytic function may not be a result of deficiency in LAL
expression as atherosclerosis progresses but rather a decrease in
the catalytic activity of LAL as a result of excess lysosomal choles-
terol accumulation from modified forms of LDL (Figure 3). LAL
remains catalytically active initially but over time FC in the lysoso-
mal membrane increases and inhibits the proton pumping ability
of the v-ATPases. As a result, the pH of the lysosome increases and
renders LAL catalytically inactivate. Lysosomal CE accumulation
then occurs in addition to cytosolic accumulation in later stage
atherosclerotic lesions.
Previous studies in atherosclerotic tissue have indicated that
LAL activity is increased relative to non-atherosclerotic arteries
(Brecher et al., 1977; Takano, 1978; Subbiah, 1979; Haley et al.,
1980; Davis et al., 1985). The analytical procedures for those stud-
ies, however, involved ex vivo acidic pH adjustment and therefore
reflects the total amount of potentially active LAL present, but
not what may be actually active in vivo within intact cells under
the influence of excess lipids and altered lysosomal pH. As activ-
ity is also reflective of protein amount, these studies may indicate
that LAL expression increases to deal with the increased cellu-
lar influx of apoB containing particles within the artery wall. It
can be proposed that LAL activity and protein amount in arterial
cells increases with lipid challenge up to a certain point, either
from increased LAL expression per cell or an increase in total
LAL-expressing cells, after which the lysosome is overwhelmed
with lipids and the activity of LAL decreases due to increased pH
caused by excess lysosomal membrane cholesterol and leakiness.
INDICATIONS OF A LYSOSOMAL CHOLESTEROL
TRAFFICKING DEFECT
The question then arises what is responsible for the elevation
of lysosomal FC in response to the excess lipoprotein load in
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FIGURE 3 | Loss of lysosomal function with excess lipid loading. (A)
CE from excess modified LDL is hydrolyzed by LAL to produce FC. (B)
Sequestration of FC in lysosomal membrane leading to increase in pH as
a result of inhibition of ATPase proton pumping ability. (C) Impairment of
LAL activity as a result of increased pH leading to CE accumulation in
lysosomes.
the intima. As NPC1 and NPC2 facilitate the release of FC
from the lysosome, investigation of the expression and activ-
ity of these proteins may provide useful insight in this area.
Previous studies in fibroblasts have suggested that retention of
cholesterol within lysosomal compartments may serve to pro-
tect cells from endoplasmic reticulum (ER) stress caused by an
excess of FC in the ER membrane. Garver et al. (2008) and
Jelinek et al. (2009) found that loading normal human fibrob-
lasts with LDL results in reduced SREBP-dependent expression
of NPC1 and NPC2. Jelinek et al. (2012) reported that in a
mouse model of diet induced obesity, dietary fatty acids but
not cholesterol induced down regulation of NPC1 in both hep-
atic cells and peritoneal fibroblasts via feedback inhibition of the
SREBP pathway. In THP-1 macrophages it has been reported that
oxLDL treatment for 3 days leads to a buildup of NPC1 pro-
tein in the Golgi apparatus (Jerome et al., 2002). Differential
responses to cholesterol-dependent manipulations of NPC1 and
NPC2 expression have been indicated in the literature. Rigamonti
et al. (2005) demonstrated that expression of NPC1 and NPC2
increased in the presence of LXR agonists in human but not
mouse macrophages. It has also been demonstrated that treat-
ment of human macrophages with oxLDL leads to increases in
NPC1 and NPC2 expression via PPARα- and mitogen-activated
protein kinase (MAPK)-dependent pathways (Chinetti-Gbaguidi
et al., 2005; Yu et al., 2012). These results indicate that the expres-
sion of NPC1 and NPC2 with lipid overload varies between cell
types and species. Further investigation is needed to elucidate the
reason for FC overload in the lysosomes of atherosclerotic foam
cells.
As the rate of release of FC from the lysosome is a regulator of
ABCA1 expression, lysosomal dysfunction in atherosclerosis may
also lead to decreased expression of ABCA1 in artery wall cells.
Choi et al. (2009) have reported that model human intimal SMCs
as well as human coronary artery intimal SMCs express lower
levels of ABCA1 than medial SMCs. More recently, Allahverdian
et al. (2014) reported that intimal SMCs but not myeloid lin-
eage cells express lower levels of ABCA1 in late vs. early stage
human atherosclerotic lesions. Further studies are required to
determine whether decreased LAL catalytic activity as a result
of lysosomal dysfunction is responsible for this defect in ABCA1
expression, and hence further contributing to the overaccumula-
tion of cholesterol in intimal SMC foam cells.
LAL AUGMENTATION IN ATHEROSCLEROSIS
Recombinant human LAL (rhLAL) is currently in phase 3 clin-
ical trials to treat LAL deficiency in Wolman disease and CESD.
This treatment is potentially life-saving in Wolman disease. Phase
2 clinical trials in patients with CESD using rhLAL demonstrated
safety and improvements in serum lipid profiles (Balwani et al.,
2013). Long-term follow up will be needed in CESD patients to
determine outcomes in terms of cardiovascular events. Several
studies in mice have indicated that rhLAL may be beneficial in
reversing atherosclerosis. Studies by Du et al. (2001) and Sun
et al. (2014) demonstrated that injection of rhLAL into LAL−/−
mice was able to reverse the pathogenic storage of lipids in mul-
tiple tissues. Du et al. (2004) also showed that administration of
repeat doses of rhLAL to LDL-receptor-deficient mice fed a high
fat/cholesterol diet resulted in complete regression of early stage
lesions in coronary and aortic tissue and a significant reduction
in late stage lesions.
Although rhLAL treatment seems to be a viable therapeu-
tic strategy for premature atherosclerosis in CESD patients, it
is unclear what the effects would be of rhLAL treatment in
patients having atherosclerosis unrelated to a deficiency in LAL.
The lysosomal acid lipase A (LIPA) gene has been identified
as a susceptibility gene for coronary artery disease by several
genome-wide association studies (Consortium, 2011; Coronary
Artery Disease Genetics, 2011; Wild et al., 2011). For the rea-
sons outlined here, increasing the activity of LAL beyond the
normal cellular response may not be an effective strategy. As scav-
enger receptor mediated uptake of modified forms of LDL in
both macrophages and SMCs occurs in atherosclerotic lesions,
it is conceivable that rhLAL treatment might increase lysosomal
membrane FC in these cells by increasing the rate of lipopro-
tein CE hydrolysis, and thereby exacerbate lysosomal dysfunction.
Reducing the level of atherogenic lipoproteins in plasma and their
initial influx into the artery wall, therefore, remains of paramount
importance.
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CONCLUSION
The role of LAL in the progression of atherosclerosis is com-
plex. Modified forms of LDL such as oxLDL and aggLDL lead
to lysosomal accumulations of first FC and later CE, indicating
an acquired loss of LAL hydrolytic activity. In agreement with
this observation, tissue studies have indicated increased lysoso-
mal lipid accumulations in addition to cytosolic lipid droplets
at later stages of atherosclerosis. Activity assays of atherosclerotic
tissue homogenates have indicated an increase in LAL and also
other lysosomal enzymes. As these studies are conducted ex vivo
using acidic pH adjustment, they are representative of potentially
functional LAL present in vivo but not necessarily actual LAL
activity. Therefore, although the amount of artery wall LAL may
increase in response to increased cellular influx of apoB-100 con-
taining lipoproteins, the hydrolytic activity of LAL may decrease
over time as lysosomal function is impaired. Sequestration of
cholesterol in the lysosomal membrane has been implicated as
a cause of lysosomal dysfunction, specifically through the inhi-
bition of v-ATPase proton pumping. Increasing lysosomal pH
reduces the activity of LAL. The result of this is a time depen-
dent switch of lysosomal accumulation of FC to CE. Early stage
atherosclerosis may involve normal and perhaps increased LAL
activity leading to cytosolic lipid droplet accumulation, whereas
later stages of atherosclerosis may have an acquired dysfunction in
LAL hydrolytic activity leading to lysosomal lipid sequestration.
Therefore, later stages of atherosclerosis, where LAL function is
inhibited, may be considered to be morphologically similar to
Wolman disease and CESD, albeit for an entirely different reason.
Outside of alleviating premature onset of atherosclerosis asso-
ciated with genetic deficiency in LAL, it is hard to predict whether
augmentation of LAL is a good therapeutic strategy. There
are indications that selective upregulation of the autophagic-
lysosomal pathway may be able to recover lysosomal function
and LAL hydrolysis. It is unclear, however, whether induction of
this pathway beyond normal response is a viable in vivo strat-
egy. Further research is necessary to know whether manipulation
of arterial cell LAL activity is likely to alleviate or aggravate the
consequences of cholesterol accumulation in the artery wall.
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